Yiting Wang
- Urology top 2%
- Rheumatology top 5%
- Spondyloarthritis Studies and Treatments 2
- Hepatology top 10%
- Orthopedics and Sports Medicine top 10%
-
- Lung Cancer Treatments and Mutations 3
- Renal cell carcinoma treatment 2
-
- Cancer Mechanisms and Therapy 3
-
- Colorectal Cancer Treatments and Studies 3
- Inflammatory Biomarkers in Disease Prognosis 3
-
- Reproductive Biology and Fertility 2
-
- Cancer-related molecular mechanisms research 2
Yiting Wang
34 papers receiving 893 citations
Hit Papers
Peers
Comparison fields: 5 of 98
- Urology 195
- Rheumatology 178
- Applied Microbiology and Biotechnology 22
- Hepatology 81
- Orthopedics and Sports Medicine 88
Countries citing papers authored by Yiting Wang
This map shows the geographic impact of Yiting Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiting Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiting Wang more than expected).
Fields of papers citing papers by Yiting Wang
This network shows the impact of papers produced by Yiting Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiting Wang. The network helps show where Yiting Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yiting Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 4 | |
| 5 | 2023 | 10 | |
| 6 | MiR-138 Suppresses the PDK1 Expression to Decrease the Oxaliplatin Resistance of Colorectal Cancer | 2020 | 1 |
| 7 | A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies | 2020 | 4 |
| 8 | Incidence, Predictors, and Prognosis of Coronary Slow-Flow and No-Reflow Phenomenon in Patients with Chronic Total Occlusion Who Underwent Percutaneous Coronary Intervention | 2020 | 5 |
| 9 | 2020 | 12 | |
| 10 | 2020 | 3 | |
| 11 | 2016 | 1 | |
| 12 | 2014 | 11 | |
| 13 | Basic science and clinical application of platelet-rich plasma for cartilage defects and osteoarthritis: a reviewbreakdown → | 2013 | 271 |
| 14 | 2012 | 14 | |
| 15 | 2011 | 14 | |
| 16 | 2008 | 152 | |
| 17 | 2008 | 144 | |
| 18 | 2007 | 58 | |
| 19 | p53 status is more likely than basal subtype to predict survival in African-American women with breast cancer | 2006 | 1 |
| 20 | 2004 | 46 |
About Yiting Wang
Yiting Wang is a scholar working on Oncology, Internal Medicine, Complementary and Manual Therapy, Pathology and Forensic Medicine and Rheumatology, having authored 40 papers that have together received 921 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (3 papers), Cancer Mechanisms and Therapy (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Inflammatory Biomarkers in Disease Prognosis (3 papers), Renal cell carcinoma treatment (2 papers), Reproductive Biology and Fertility (2 papers), Spondyloarthritis Studies and Treatments (2 papers) and Cancer-related molecular mechanisms research (2 papers). The work is most often cited by research in Urology (195 citations), Rheumatology (178 citations), Applied Microbiology and Biotechnology (22 citations), Hepatology (81 citations) and Orthopedics and Sports Medicine (88 citations). Yiting Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Quanyi Guo, Jiang Peng, Ming Yuan, Yeqing Zhu, Pharis Mohideen, Jacqueline Barona, Markus Niggli, Changyu Pan, James E. Foley and Wenying Yang. Their work appears in journals such as Clinical Radiology, Journal of Oral Rehabilitation, Clinical Infectious Diseases, Clinical Cancer Research and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.